APOPTOTIC AND MITOTIC ACTIVITY IN SQUAMOUS CELL CARCINOMA CELLS AFTER COMBINED MODALITY TREATMENT WITH γ‐IRRADIATION AND DIBROMODULCITOL

A‐431 squamous cell carcinoma cells were treated in vitro with either 4Gy radiatio of 15 (or 45) μg/ml dibromodulcitol (DBD), as well as with combined 4Gy irradiation and DBD, with the latter as either a pretreatment or post‐treatment. DBD alone or in combination with radiation had a greater effect on cell proliferation than the effect of radiation alone. The difference is due to a higher level of apoptosis induced by DBD, especially in conjunction with radiation. Such a combination may therefore be useful in the treatment of squamous cell carcinoma, which in general responds poorly to radiation therapy.

[1]  D. Áfra,et al.  Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas , 1994, Neurology.

[2]  L. Olasz,et al.  A combined treatment for advanced oral cavity cancers , 1988, Cancer.

[3]  D. Áfra,et al.  Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas. , 1983, Journal of neurosurgery.

[4]  E. Institóris,et al.  Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine. , 1980, The Biochemical journal.

[5]  K. Lapis,et al.  Chromatin proteins as a possible target for antitumour agents: alterations of chromatin proteins in dibromodulcitol treated Yoshida tumors. , 1979, Chemico-biological interactions.

[6]  F. Cavalli.  [New substances in oncologic therapy]. , 1978, Schweizerische medizinische Wochenschrift.

[7]  K. Brunner,et al.  Neue Substanzen in der onkologischen Therapie , 1978 .

[8]  B. Fox,et al.  The interaction of dianhydrogalactitol with DNA in cultured Yoshida sarcoma cells. , 1978, Chemico-biological interactions.

[9]  L. Szabó,et al.  The effect of dibromo-dulcitol, diepoxy dulcitol and various new cytostatic hexitol derivatives on the metabolic activities of nucleic acids and proteins--II. , 1976, Biochemical pharmacology.

[10]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[11]  E. Institóris,et al.  Interaction of cytotoxic dibromohexitols with albumin. , 1971, Biochemical pharmacology.

[12]  T. Valyi-Nagy,et al.  Pharmaco-biochemical studies on cytotoxic polyol derivatives. II. The effect of biological alkylating agents on the thermal-denaturation properties of DNA. , 1970, European journal of cancer.

[13]  J. Kralovánszky,et al.  Clinical and pharmacologic experience with dibromodulcitol (NSC-104800). A new antitumor agent. , 1969, Cancer chemotherapy reports.

[14]  P. Lonai,et al.  The effect of mannitol-myleran and two new dibromo-hexitols on the metabolic activities of nucleic acids and proteins. I. , 1967, Biochemical pharmacology.

[15]  Z. Szentirmay,et al.  Search for prognostic factors in head and neck cancer. , 1997, Acta oto-laryngologica. Supplementum.

[16]  P. Herczegh,et al.  A comparative study of preoperative B-V-M-M chemotherapy and irradiation in advanced squamous cell cancer of the oral cavity. , 1996, Neoplasma.

[17]  D. Schuler,et al.  Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children. , 1992, Medical and pediatric oncology.

[18]  L. Olasz,et al.  An effective combined therapy for advanced squamous cell carcinoma of the oral cavity: preoperative BVMM (bleomycin, vincristine, mitolactol plus methotrexate and leucovorin) chemotherapy followed by surgery. , 1988, Neoplasma.

[19]  T. Révész,et al.  Dibromdulcitol containing chemotherapeutic regimen in the treatment of childhood Hodgkin's disease. , 1988, Neoplasma.

[20]  I. Bodrogi,et al.  Forms and results of mitolactol therapy. , 1980, Oncology.

[21]  K. Lapis,et al.  Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study. , 1976, Neoplasma.

[22]  J. V. Ryzin,et al.  A Phase III Study in Lung Carcinoma Comparing Hexamethylmelamine (NSC 13875) to Dibromodulcitol (NSC 104800) , 1975 .